TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21315654
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg preladenant
Study: 21315654
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg preladenant
Study: 16310713
Drug: 0.33 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.33 mg/kg oral active placebo (diphenhydramine)
Study: 11124360
Drug: both preparations
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: both preparations
Study: 9286937
Drug: Aspirin (320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (320 mg/d)
Study: 9286937
Drug: Indobufen (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indobufen (200 mg BID)
Study: 26696645
Drug: Hypothermia group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypothermia group (standard medical treatment plus endovascular hypothermia with a target temperature of 33 or 34°C for a minimum of 24 hours)
Study: 26696645
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard medical treatment only with a target temperature of normothermia)
Study: 24929428
Drug: Low-glycemic-load diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-glycemic-load diet with ALA and MUFA (canola oil-enriched bread supplement, 31 g canola oil per 2,000 kcal)
Study: 24929428
Drug: Whole-grain diet
Normalized name: rice (whole grain) allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-grain diet with whole-wheat bread supplement (control)
Study: 24929428
Drug: Low-glycemic-load diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-glycemic-load diet with ALA and MUFA (canola oil-enriched bread supplement)
Study: 12808702
Drug: PFME therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PFME therapy with health education program
Study: 12808702
Drug: PFME therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PFME therapy alone
Study: 12808702
Drug: PFME therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PFME therapy
Study: 8869311
Drug: Standard 18-G
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard 18-G Teflon cannula, removed on completion of infusion, rotated to contralateral arm daily (Group 1)
Study: 8869311
Drug: Similar catheter
Normalized name: CATHETER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Similar catheter sited in each forearm, rotation of side of infusion daily (Group 2)
Study: 8869311
Drug: 15-cm Silastic
Normalized name: CATHETER SILASTIC 14FR 5CC
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15-cm Silastic rubber catheter in one forearm and standard cannula in contralateral forearm, alternation of infusion daily (Group 3)
Study: 8869311
Drug: Fine-bore 23-G
Normalized name: calcium gluconate
DrugBank: Calcium gluconate (DB11126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fine-bore 23-G silicone catheter sited in one arm only, fed continuously over 24 hours (Group 4)
Study: 1505607
Drug: Nicardipine 60
Normalized name: niCARdipine 60 mg oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine 60 mg/day, in three spaced doses for one month
Study: 26939716
Drug: Control condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control condition of standard secondary and specialist primary care treatment
Study: 17309330
Drug: Cervarix vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervarix vaccine (bivalent L1 virus-like particle vaccine against HPV types 16 and 18)
Study: 11752031
Drug: Prednisolone and
Normalized name: prednisolone and mydriatics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone and cytotoxic agents
Study: 11752031
Drug: Low-dose cyclophosphamide
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cyclophosphamide then azathioprine
Study: 12316339
Drug: Combined low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Combined low-dose estrogen and progesterone pills
Study: 843794
Drug: Dipyridamole (alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole (alone and in combination with aspirin)
Study: 29406177
Drug: Thirst-driven fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thirst-driven fluid administration (200 ml bolus triggered by participants)
Study: 29406177
Drug: Thirst-driven fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thirst-driven fluid administration
Study: 29406177
Drug: Clinician-directed fluid
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinician-directed fluid management (1.25 ml kg‐1 h‐1 with 500 ml bolus)
Study: 23328379
Drug: CIK via
Normalized name: Human parathyroid hormone (PTH) synthetic peptide fragment (1-34), conjugated at the N-terminal amino group via a cleavable linker to O-methylpolyethylene glycol (2 x 20 kDa mPEG); 2-methylalanyl-(1-34)-peptide of parathyroid hormone (Homo sapiens parath
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIK via intravenous drop infusion for more than 6 times (study group)
Study: 18611068
Drug: Anti-adhesion molecule
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-adhesion molecule therapy; specific agents not mentioned
Study: 18611068
Drug: Anti-TNF therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-TNF therapy (infliximab, adalimumab)
Study: 16025962
Drug: Puerarin injection
Normalized name: PUERARIA MIRIFICA ROOT
DrugBank: Puerarin (DB12290)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Puerarin injection (PI)
Study: 11432713
Drug: Vitamins/mineral and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamins/mineral and garlic preparation
Study: 2907349
Drug: bopindolol, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: bopindolol, 1 mg once daily for 1 week
Study: 2907349
Drug: atenolol, 50
Normalized name: Atenolol, 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: atenolol, 50 mg once daily for 1 week
Study: 2907349
Drug: adrenaline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: adrenaline infusion (20 ng/kg per min)
Study: 1929842
Drug: Allopurinol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (50 mg per rectum, four times per day)
Study: 1929842
Drug: Dimethyl sulfoxide
Normalized name: Dimethyl Sulfoxide
DrugBank: Dimethyl sulfoxide (DB01093)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dimethyl sulfoxide (500 mg per rectum, four times per day)
Study: 1929842
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no radical scavengers, only analgesic regimen)
Study: 324238
Drug: G 31.406
Approvals — FDA: no, EMA: no, PMDA: no
Description: G 31.406
Study: 9676837
Drug: Oral 13‐cis‐retinoic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 13‐cis‐retinoic acid at a dose of 1 mg/kg
Study: 7740961
Drug: Timopentina (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timopentina (50 mg/3 times per week for 6 weeks, 4 or 5 cycles during the year)
Study: 2691169
Drug: Experimental dental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental dental rinse (15 ml, rinsed for 30 seconds)
Study: 5332751
Drug: Analgesic-sedative combination
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesic-sedative combination (Fiorinal-C(1/4))
Study: 5332751
Drug: Analgesic (APC-C)
Normalized name: ANALGESIC CREAM
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesic (APC-C)
Study: 27138893
Drug: School-based Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: School-based Cognitive Behavioural Therapy (CBT)
Study: 26702925
Drug: Ceftaroline fosamil
Normalized name: Ceftaroline fosamil
DrugBank: Ceftaroline fosamil (DB06590)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftaroline fosamil (600 mg every 12 h)
Study: 8215267
Drug: Ceftriaxone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (2 g every 24 h)
Study: 21571593
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg fingolimod
Study: 21571593
Drug: 1.25 mg
Normalized name: menthol 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg fingolimod
Study: 21571593
Drug: Interferon beta‐1a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon beta‐1a to 0.5 mg fingolimod
Study: 21571593
Drug: Interferon beta‐1a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon beta‐1a to 1.25 mg fingolimod
Study: 17171925
Drug: High-dose fentanyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose fentanyl (75 microg/kg followed by 0.3 microg/kg/min)
Study: 17171925
Drug: Diazepam-ketamine (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam-ketamine (0.8 mg/kg D and 2 mg/kg K followed by 0.07 mg/kg/h D and 1 mg/kg/h K)
Study: 30514262
Drug: Metformin (850
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (850 mg bis in die)
Study: 30514262
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of aspirin and metformin
Study: 30514262
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and Metformin
Study: 20922480
Drug: Workload score
Normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Workload score based on the number of drugs involved, type of literature search performed, and judgmental categorization.
Study: 20922480
Drug: Number of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Number of drugs involved.
Study: 10029561
Drug: Formoterol, 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol, 12 microg once daily
Study: 10029561
Drug: Formoterol, 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol, 6 microg twice daily
Study: 10029561
Drug: Formoterol, 24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol, 24 microg twice daily
Study: 10029561
Drug: Terbutaline, 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline, 500 microg four times daily
Study: 10029561
Drug: Lower doses
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower doses of formoterol (12 microg once daily or 6 microg twice daily)
Study: 7479225
Drug: Propranolol (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (0.1 mg/kg) and atropine (0.02 mg/kg)
Study: 4065106
Drug: Domperidone, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone, 10 mg
Study: 4065106
Drug: Atropine, 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine, 0.6 mg
Study: 31487627
Drug: Alternative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative treatment
Study: 27866177
Drug: Cranberry juice
Normalized name: cranberry juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry juice (4 oz daily for 6 months)
Study: 22816441
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of all devices
Study: 12548091
Drug: Intravenous treprostinil
Normalized name: Treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous treprostinil
Study: 18536066
Drug: WSKY capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: WSKY capsule added on risperidone
Study: 15572397
Drug: Retrospective dosimetry
Normalized name: 3-iodobenzylguanidine
DrugBank: Iobenguane (DB06704)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retrospective dosimetry using FISH translocations for patients with lower earlier dose estimates (up to about 3 Gy)
Study: 15572397
Drug: Retrospective dosimetry
Normalized name: 3-iodobenzylguanidine
DrugBank: Iobenguane (DB06704)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retrospective dosimetry using FISH translocations for patients with higher earlier dose estimates (up to about 12 Gy)
Study: 10471984
Drug: Gabapentin 400
Normalized name: gabapentin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 400 mg three times daily for 2 weeks
Study: 10471984
Drug: Phenytoin 100
Normalized name: phenytoin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenytoin 100 mg three times daily for 2 weeks
Study: 8560996
Drug: Minprostin gel
Normalized name: Minprostin F2 Alpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minprostin gel (0.5 mg intracervical Gel)
Study: 8560996
Drug: Minprostin tablets
Normalized name: Minprostin F2 Alpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minprostin tablets (3 mg vaginal tablets)
Study: 8478315
Drug: Dirithromycin (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dirithromycin (two 250 mg tablets, once daily)
Study: 8478315
Drug: Erythromycin (four
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (four 250 mg tablets, four times daily)
Study: 29254080
Drug: 20-mg telmisartan
Normalized name: telmisartan 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-mg telmisartan (Micardis)
Study: 29254080
Drug: 40-mg telmisartan
Normalized name: telmisartan 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40-mg telmisartan (Micardis)
Study: 24257146
Drug: Subfascial catheter
Normalized name: CATHETER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subfascial catheter with continuous levobupivacaine infusion (Group S)
Study: 24257146
Drug: Epidural analgesia
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural analgesia with continuous levobupivacaine infusion (Group E)
Study: 23109696
Drug: CAP45 (45-Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAP45 (45-Gy RT for 5 weeks with concurrent capecitabine)
Study: 23109696
Drug: CAPOX50 (50-Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAPOX50 (50-Gy RT for 5 weeks with concurrent capecitabine and oxaliplatin)
Study: 18088035
Drug: Continuous physical
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous physical training (4 to 5 times weekly for 6 months)
Study: 15571617
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with cisplatin, ifosfamide, and doxorubicin followed by radiotherapy
Study: 12206448
Drug: Bupropion SR
Normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion SR 300 mg/day (150 mg b.i.d.)
Study: 9405728
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist treatment for 6 months
Study: 8949572
Drug: Intravenous GH
Normalized name: FUSION PROTEIN OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG- .BETA.)-(118-145)-PEPTIDE (1-28) WITH HUMAN SOMATOTROPIN (GROWTH HORMONE, GH) (29-219) AND TWO TANDEM COPIES OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG-.BETA.)-(118-145)- PEPTIDE (220-247
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous GH infusion (0.03 microgram (0.1 mU/kg/min) for 39 hours)
Study: 8949572
Drug: Subcutaneous GH
Normalized name: FUSION PROTEIN OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG- .BETA.)-(118-145)-PEPTIDE (1-28) WITH HUMAN SOMATOTROPIN (GROWTH HORMONE, GH) (29-219) AND TWO TANDEM COPIES OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG-.BETA.)-(118-145)- PEPTIDE (220-247
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous GH infusion (0.03 microgram (0.1 mU/kg/min) for 39 hours)
Study: 8949572
Drug: Intravenous GH
Normalized name: FUSION PROTEIN OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG- .BETA.)-(118-145)-PEPTIDE (1-28) WITH HUMAN SOMATOTROPIN (GROWTH HORMONE, GH) (29-219) AND TWO TANDEM COPIES OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG-.BETA.)-(118-145)- PEPTIDE (220-247
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous GH infusion
Study: 8949572
Drug: Subcutaneous GH
Normalized name: FUSION PROTEIN OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG- .BETA.)-(118-145)-PEPTIDE (1-28) WITH HUMAN SOMATOTROPIN (GROWTH HORMONE, GH) (29-219) AND TWO TANDEM COPIES OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG-.BETA.)-(118-145)- PEPTIDE (220-247
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous GH infusion
Study: 8949572
Drug: GH administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GH administration (both routes)
Study: 8949572
Drug: Both routes
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both routes of GH administration
Study: 1672803
Drug: atracurium 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: atracurium 0.6 mg.kg‐1
Study: 1672803
Drug: half‐dose combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: half‐dose combinations of atracurium and vecuronium
Study: 1672803
Drug: quarter‐dose combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: quarter‐dose combinations of atracurium and vecuronium
Study: 1672803
Drug: full‐dose combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: full‐dose combinations of atracurium and vecuronium
Study: 7043395
Drug: Piribedil (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piribedil (0.1 mg/kg over 30 minutes)
Study: 7043395
Drug: Domperidone (prior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone (prior administration)
Study: 27716691
Drug: Dexmedetomidine 1
Normalized name: DEXMEDETOMIDINE 120MCG SUBLINGUAL FILM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 1 mcg/kg IV over 20 min followed by 0.5 mcg/kg/h for 72 h postoperative
Study: 27716691
Drug: Amiodarone 5
Normalized name: amiodarone 50 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone 5 mg/kg IV over 20 min followed by 10-15 mcg/kg/h for 72 h postoperative
Study: 19229114
Drug: Probiotic yogurt
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic yogurt (300 g/day for 6 weeks)
Study: 19229114
Drug: Ordinary yogurt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ordinary yogurt (300 g/day for 6 weeks)
Study: 11261907
Drug: Ketamine 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.3 mg/kg and 2% lignocaine infiltration
Study: 11261907
Drug: Ketamine 0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.9 mg/kg and diazepam 0.07 mg/kg
Study: 7735519
Drug: Olea europaea
Normalized name: OLEA EUROPAEA LEAF
DrugBank: Olea europaea leaf (DB14745)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olea europaea pollen extract (immunotherapy)
Study: 1684178
Drug: Broxaterol patch
Normalized name: procaterol
DrugBank: Procaterol (DB01366)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broxaterol patch (size = 1.75 cm2; programmed delivery = 105 mcg/h)
Study: 6819891
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition (TPN) with constant infusion of hypertonic glucose and amino acids by central vein (35 kcal/kg/day)
Study: 23863050
Drug: Radium-223 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radium-223 (50 kBq/kg IV, six injections every 4 weeks)
Study: 23863050
Drug: Placebo (matching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (matching injections every 4 weeks)
Study: 22101697
Drug: Xinfeng capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xinfeng capsule (XFC), 3 capsules, thrice a day for 30 days (2 courses)
Study: 22101697
Drug: Fengshi gutong
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fengshi gutong capsule (FSGTC), 4 capsules, twice a day for 30 days (2 courses)
Study: 26591677
Drug: Xinfeng capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xinfeng capsule (XFC)
Study: 15361940
Drug: Gabexate mesilate
Normalized name: mesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabexate mesilate (GM) at 1 mg/kg/hour for 5 days or longer
Study: 9673806
Drug: Physical Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical Therapy (PT) as an adjunct treatment
Study: 3149884
Drug: Topical mupirocin
Normalized name: mupirocin Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical mupirocin (3 daily applications for 8 days)
Study: 3149884
Drug: Oral erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral erythromycin ethylsuccinate (40 mg/kg/day divided into four doses for 8 days)
Study: 25515106
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy for Insomnia (CBT-I) - single 60-70 minute session with self-help pamphlet (n = 20)
Study: 25623312
Drug: Pectin (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pectin (24 g/d for 4 weeks)
Study: 18358071
Drug: 300 mg/day
Normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg/day SDG
Study: 18358071
Drug: 600 mg/day
Normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg/day SDG
Study: 18358071
Drug: 0 mg/day
Normalized name: RibaTab 800 mg/day Compliance Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg/day SDG (placebo)
Study: 17302251
Drug: Ritonavir-boosted low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ritonavir-boosted low-dose indinavir (200 mg twice daily) and lamivudine (150 mg twice daily)
Study: 17302251
Drug: Ritonavir-boosted low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ritonavir-boosted low-dose indinavir and lamivudine
Study: 12957192
Drug: Enfuvirtide (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enfuvirtide (90 mg twice daily) at injection site: abdomen
Study: 12957192
Drug: Enfuvirtide (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enfuvirtide (90 mg twice daily) at injection site: thigh
Study: 12957192
Drug: Enfuvirtide (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enfuvirtide (90 mg twice daily) at injection site: arm
Study: 12957192
Drug: Enfuvirtide (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enfuvirtide (90 mg twice daily)
Study: 9437183
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (4 g daily equivalent to 0.91 g n‐3 VLCPUFA)
Study: 4036847
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg cholesterol daily
Study: 4036847
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg cholesterol daily